Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint, reductions in lesion growth rate, in the pivotal, global Phase 3 ...

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint, reductions ...

The annual conference of the Biotechnology Innovation Organization (BIO) is always an anticipated gathering where pharma and biotech leaders and policymakers meet to discuss the challenges facing ...

ImmunityBio to serve as sole U.S. Biologics License Application applicant for the Tokyo strain of BCG and plans to engage with U.S. Food and Drug Administration (FDA) on regulatory pathway to address ...

Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal ...

Cabaletta Bio (CABA) remains a Buy: rese-cel trial catalysts, autoimmune upside, scalable manufacturing, and key risks like ...

Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the ...

Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable ...

There are also shampoos and scalp care products available which claim to promote healthy hair growth ...

Bank of America Global Healthcare Conference 2026 May 12, 2026 5:20 PM EDTCompany ParticipantsThomas Trimarchi - CFO ...